NYSE$UHS
Universal Health Services Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
UHS's financial performance declined in Q3 2022, with decreased net income and earnings per share compared to Q3 2021.
Universal Health Services, Inc. reported a decrease in net income attributable to UHS to $182.8 million, or $2.50 per diluted share, during the third quarter of 2022, compared to $218.4 million, or $2.60 per diluted share, during the third quarter of 2021. Net revenues increased by 5.7% to $3.336 billion during the third quarter of 2022 as compared to $3.156 billion during the third quarter of 2021.
- Net income attributable to UHS decreased to $182.8 million, or $2.50 per diluted share, compared to $218.4 million, or $2.60 per diluted share in Q3 2021.
- Adjusted net income attributable to UHS decreased to $185.8 million, or $2.54 per diluted share, compared to $224.1 million, or $2.67 per diluted share in Q3 2021.
- Net revenues increased by 5.7% to $3.336 billion compared to $3.156 billion in Q3 2021.
- EBITDA net of NCI was $421.7 million, compared to $441.5 million in Q3 2021.
Headline financials
Revenue & EPS history
UHS · Revenue · Quarterly
$3.34B
Revenue by segment
UHS · $3.35B total across 2 segments · Q3 2022
- Acute Care Services$1.92B+5.4%57.2%
- Behavioral Health Services$1.43B+8.0%42.8%
Forward guidance
Revised operating results forecast for the balance of 2022 assumed that staffing vacancies and the corresponding premium pay expenditures continue to sequentially decline in the second half of the year and that non-COVID patient volumes will incrementally improve, although both at a slower pace than our original forecast anticipated.
Tailwinds
- Continuing recruitment and retention initiatives
- Changes to historical patient care models
- Other cost cutting measures
- Aggressive contractual negotiations
- Renegotiations with managed care payers
Headwinds
- Potential impact on future COVID-19 patient volumes resulting from new variants of the virus
- The length of time and severity of the spread of the pandemic
- Declining patient volumes and unfavorable changes in payer mix caused by deteriorating macroeconomic conditions
- Potential disruptions to our clinical staffing and shortages and disruptions related to supplies required for our employees and patients
- Potential increases to expenses and other costs related to staffing, supply chain, construction and medical equipment costs and other expenditures resulting from inflation
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+0.3%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+0.7%
Avg return
30 days after
49%
34 / 69 earnings
Positive
+17.5%
Q3 2022
Best reaction
-13.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.5% | -7.0% | -16.4% | |
| Q4 2025 | -5.5% | -1.0% | -9.9% | |
| Q3 2025 | +2.5% | +1.4% | +14.1% | |
| Q2 2025 | -0.2% | +3.3% | +7.3% | |
| Q1 2025 | -0.6% | +3.4% | +10.5% | |
| Q4 2024 | +3.3% | -3.8% | +3.4% | |
| Q3 2024 | -13.4% | -12.1% | -15.5% | |
| Q2 2024 | +10.6% | +17.3% | +25.8% | |
| Q1 2024 | +0.1% | +2.6% | +6.9% | |
| Q4 2023 | -1.6% | +4.1% | +11.0% | |
| Q3 2023 | -0.2% | -0.6% | +11.4% | |
| Q2 2023 | -4.6% | -6.5% | -12.3% | |
| Q1 2023 | +1.5% | +6.9% | -9.3% | |
| Q4 2022 | -9.1% | -13.5% | -15.5% | |
| Q3 2022 | +17.5% | +25.8% | +39.3% | |
| Q2 2022 | -1.5% | +1.3% | -5.7% | |
| Q1 2022 | -5.7% | -7.8% | -8.1% | |
| Q4 2021 | +8.6% | +8.7% | +11.1% | |
| Q3 2021 | -7.0% | -8.5% | -5.0% | |
| Q2 2021 | +4.2% | +5.1% | +1.6% | |
| Q1 2021 | +0.3% | +2.0% | +10.1% | |
| Q4 2020 | -9.1% | -6.2% | -2.0% | |
| Q3 2020 | +3.0% | +11.1% | +24.2% | |
| Q2 2020 | +0.9% | +1.7% | +0.2% | |
| Q1 2020 | +3.7% | -2.5% | +8.6% | |
| Q4 2019 | -5.3% | -2.7% | -34.3% | |
| Q3 2019 | -4.6% | -4.0% | -3.6% | |
| Q2 2019 | +10.9% | +11.6% | +4.7% | |
| Q1 2019 | -0.8% | -2.6% | -5.5% | |
| Q4 2018 | +3.9% | +2.7% | +0.1% | |
| Q3 2018 | -5.3% | -1.0% | +8.0% | |
| Q2 2018 | +9.3% | +9.3% | +12.0% | |
| Q1 2018 | -4.6% | -5.2% | -3.2% | |
| Q4 2017 | -1.3% | +5.3% | +0.7% | |
| Q3 2017 | -6.9% | -8.3% | -9.9% | |
| Q2 2017 | -9.2% | -10.3% | -12.6% | |
| Q1 2017 | -2.0% | -0.1% | -3.0% | |
| Q4 2016 | -0.9% | -0.8% | -0.8% | |
| Q3 2016 | +0.6% | -0.7% | +1.3% | |
| Q2 2016 | -4.4% | -5.2% | -12.1% | |
| Q1 2016 | +2.1% | — | — | |
| Q4 2015 | +2.4% | — | — | |
| Q3 2015 | +2.4% | — | — | |
| Q2 2015 | +2.1% | — | — | |
| Q1 2015 | -0.7% | — | — | |
| Q4 2014 | +3.8% | — | — | |
| Q3 2014 | -1.0% | — | — | |
| Q2 2014 | +6.8% | — | — | |
| Q1 2014 | +8.3% | — | — | |
| Q4 2013 | -2.6% | — | — | |
| Q3 2013 | +2.6% | — | — | |
| Q2 2013 | +3.3% | — | — | |
| Q1 2013 | +3.3% | — | — | |
| Q4 2012 | -0.0% | — | — | |
| Q3 2012 | -3.2% | — | — | |
| Q2 2012 | +4.8% | — | — | |
| Q1 2012 | -1.7% | — | — | |
| Q2 2011 | +2.0% | — | — | |
| Q4 2011 | +2.0% | — | — | |
| Q3 2011 | +3.8% | — | — | |
| Q1 2010 | +3.8% | — | — | |
| Q4 2010 | +3.8% | — | — | |
| Q1 2011 | +3.8% | — | — | |
| Q2 2010 | +5.0% | — | — | |
| Q3 2009 | +0.0% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q4 2009 | -0.3% | — | — | |
| Q2 2009 | -0.3% | — | — | |
| Q4 2008 | -0.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro